p97-Based PROTAC Nanobody Conjugates for E3-Independent Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for protein degradation, such as conventional PROTACs, rely on ubiquitin E3 ligases, which can be limiting and inefficient, especially for large protein complexes and toxic aggregates.
Innovation Solution
A p97-based proteolysis targeting chimaera (PROTAC) is developed, utilizing a synthetic chimaera of the p97 adapter FAF1's UBX domain fused with camelid nanobodies to target specific proteins for degradation independent of ubiquitin E3 ligases, leveraging the p97 AAA ATPase's segregase activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional PROTACs using ubiquitin E3 ligases are used for protein degradation, then the degradation mechanism is well-established, but the efficiency is limited especially for large protein complexes and toxic aggregates
Solution Approach 1:
The patent introduces p97 as an intermediary mediator to replace ubiquitin E3 ligases in the protein degradation process. The p97-based PROTAC uses p97 AAA ATPase segregase activity to recognize and degrade target proteins, particularly excelling at degrading large protein complexes and toxic aggregates that conventional ubiquitin ligase-dependent methods cannot efficiently handle.
Solution Approach 2:
The patent changes the fundamental parameter of the degradation mechanism by switching from ubiquitin ligase-dependent pathways to p97 AAA ATPase-dependent pathways. This parameter change enables the system to overcome the limitations of conventional PROTACs and efficiently degrade recalcitrant targets such as large protein complexes and toxic aggregates.
2Reliability
If ubiquitin E3 ligase-dependent PROTACs are used, then the mechanism is conventional and well-understood, but it becomes limiting and inefficient for certain targets
Solution Approach 1:
The patent inverts the conventional approach by using p97 AAA ATPase activity instead of ubiquitin E3 ligase activity as the driving force for protein degradation. This inversion creates a novel degradation pathway that is more efficient and reliable for degrading specific target proteins, particularly large protein complexes and toxic aggregates that resist conventional ubiquitin ligase-based degradation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The p97-PROTAC efficiently degrades target proteins, including large complexes and toxic aggregates, by recruiting them to the proteasome for degradation, offering an alternative to conventional ubiquitin ligase-dependent methods.
Implementation Method 1
p97 is a member of the AAA+ family of ATPases. It is a mechanoenzyme that actively uses energy from ATP hydrolysis to promote protein unfolding and segregation to deliver to the proteasome for degradation.
Implementation Method 2
The p97-based proteolysis targeting chimaera (PROTAC), which facilitates the degradation of specific target proteins in a unique, Ubiquitin E3 ligase independent manner... leveraging the p97 AAA ATPase's segregase activity.
Data Source
AI summary
New system to facilitate the degradation of target proteins within cells, which uses a chimeric protein with a moiety of single-domain VHH antibodies fused with the UBX domain that is recognized by p97. Where the VHH binds proteins selectively and the UBX domain recruit the protein for p97-mediated degradation based of proteasome activity. Single-domain VHH antibodies, or Nanobody (Nb) can be attached to UBX directly or using a linker.